Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-023213
Filing Date
2025-11-14
Accepted
2025-11-14 11:59:49
Documents
69
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1605047
2 EX-31.1 ex31-1.htm EX-31.1 16594
3 EX-31.2 ex31-2.htm EX-31.2 17124
4 EX-32.1 ex32-1.htm EX-32.1 7327
5 EX-32.2 ex32-2.htm EX-32.2 7536
  Complete submission text file 0001493152-25-023213.txt   9352032

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ppcb-20250930.xsd EX-101.SCH 57616
7 XBRL CALCULATION FILE ppcb-20250930_cal.xml EX-101.CAL 67716
8 XBRL DEFINITION FILE ppcb-20250930_def.xml EX-101.DEF 307833
9 XBRL LABEL FILE ppcb-20250930_lab.xml EX-101.LAB 510252
10 XBRL PRESENTATION FILE ppcb-20250930_pre.xml EX-101.PRE 419362
71 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1376913
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-42806 | Film No.: 251483192
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)